isirv Antiviral Group
AVG Home
|
AVG Webinar Series
AVG Webinar series You can listen to the recordings from the AVG webinars which have taken place to date via the links below: 25 October 2022: Treatments/Antiviral Therapeutics - link to the recording 24 January 2023: Antiviral Resistance - link to the recording 20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording 30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording 2024 ISIRV Webinars 24 Jan If you missed the webinar on 24 Jan on 'RSV Vaccination in the Elderly Population' you can register and watch the recording via this link 20 March If you missed this webinar on 'Emerging Influenza and the Human-Animal Interface' you can register and watch the recording via this link 29 May Webinar on ‘Recent antiviral developments for respiratory viral infections’ We’re delighted to announce that we’ll have 3 speakers on this webinar. Professor Bin Cao, China-Japan Friendship Hospital, Beijing, China will give an overview talk on ‘Recent Antiviral Developments for Respiratory Viral Infections in China'. Dr Tom Fletcher, Liverpool School of Tropical Medicine, Liverpool, UK who will speak on ‘IV favipirivir’ Dr Don Ganem, Via Nova Therapeutics, Oakland, CA, USA who will speak on 'VNT-101: A Novel, Orally Bioavailable Inhibitor of Influenza A Virus Targeting the Viral Nucleoprotein, NP' You can register now via this link
7th AVG Conference (in-person)
We’ve had some great feedback….
AVG Overview
The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More
Latest… Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract… read more Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants… read more Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus… read more Outpacing antiviral resistance: new treatments for influenza virus infection… read more Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey… read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
|
Visit us on:
  Quick links:
Contact AVG:Email:avg@isirv.org |
